Abstract
PRKAA1 is the α-subunit of 5-AMP-activated protein kinase. This study aimed to investigate the role of PRKAA1 expression with multiple clinical parameters, the overall survival rate, blood indexes, and immune infiltration in gastric cancer (GC) patients. We investigated PRKAA1 expression data in GC patients using ELISA, protein atlas, UALCAN, and GEPIA. PRKAA1 expression was associated with immune cell infiltration, and immune cell types were analyzed with the TIMER, DICE, and protein atlas databases. We compared the level of PRKAA1 expression based on the clinical features of GC patients (n = 345). GC patients were divided into two groups based on PRKAA1 expression, and the lymphocyte subsets, overall survival rate, and clinical parameters were compared with peripheral blood mononuclear cell and biochemical indexes. PRKAA1 was highly expressed in the serum of GC patients compared with that of healthy individuals. GC patients with distant metastases, a later TNM stage, and stage IV in UICC exhibited higher PRKAA1 expression. PRKAA1 expression was significantly correlated with circulating T cells. The protein atlas and DICE database results confirmed that PRKAA1 was closely associated with T cells in a single-cell cluster. Furthermore, GC patients with low PRKAA1 expression had better OS rates. PRKAA1 may serve as a potential prognostic biomarker for GC and have an association with immune infiltrates.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The datasets generated during the current study are available from the corresponding author on reasonable request.
References
Carling D, Sanders MJ, Woods A (2008) The regulation of AMP-activated protein kinase by upstream kinases. Int J Obes (Lond) 32(Suppl 4):S55–S59. https://doi.org/10.1038/ijo.2008.124
Chen M, Jiang B, He B, Tang M, Wang P, Chen L, Lu J, Lu P (2018) Genetic variations in PRKAA1 predict the risk and progression of gastric Cancer. BMC Cancer 18:923. https://doi.org/10.1186/s12885-018-4818-3
Das S, Johnson DB (2019) Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer 7:306. https://doi.org/10.1186/s40425-019-0805-8
Dial AG, Ng SY, Manta A, Ljubicic V (2018) The role of AMPK in neuromuscular biology and disease.Trends. Endocrinol Metab 29:300–312. https://doi.org/10.1016/j.tem.2018.02.010
Fogarty S, Ross FA, Vara Ciruelos D, Gray A, Gowans GJ, Hardie DG (2016) AMPK causes cell cycle arrest in LKB1-deficient cells via activation of CAMKK2. Mol Cancer Res 14:683–695. https://doi.org/10.1158/1541-7786.MCR-15-0479
Fu C, Jiang A (2018) Dendritic cells and CD8 T cell immunity in tumor microenvironment. Front Immunol 9. https://doi.org/10.3389/fimmu.2018.03059
Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J et al (2018) Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol 4:e180013. https://doi.org/10.1001/jamaoncol.2018.0013
G. Dargiene, G. Streleckiene, J. Skieceviciene, M. Leja, A. Link, T. Wex, L. Kupcinskas, P. Malfertheiner and J. Kupcinskas (2018) TLR1 and PRKAA1 gene polymorphisms in the development of atrophic gastritis and gastric cancer. J Gastrointestin Liver Dis 27:363-369. https://doi.org/10.15403/jgld.2014.1121.274.tlr
Griffiths RM, Pru CA, Behura SK, Cronrath AR, McCallum ML, Kelp NC, Winuthayanon W, Spencer TE, Pru JK (2020) AMPK is required for uterine receptivity and normal responses to steroid hormones. Reproduction 159:707–717. https://doi.org/10.1530/REP-19-0402
Janjigian YY, Maron SB, Chatila WK, Millang B, Chavan SS, Alterman C, Chou JF, Segal MF, Simmons MZ, Momtaz P, Shcherba M, Ku GY, Zervoudakis A, Won ES, Kelsen DP, Ilson DH, Nagy RJ, Lanman RB, Ptashkin RN et al (2020) First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. The Lancet Oncology 21:821–831. https://doi.org/10.1016/s1470-2045
Kahraman S, Yalcin S (2021) Recent advances in systemic treatments for HER-2 positive advanced gastric cancer. Onco Targets Ther 14:4149–4162. https://doi.org/10.2147/OTT.S315252
Kono K, Nakajima S, Mimura K (2020) Current status of immune checkpoint inhibitors for gastric cancer. Gastric Cancer 23:565–578. https://doi.org/10.1007/s10120-020-01090-4
Krishan S, Richardson DR, Sahni S (2014) Gene of the month. AMP kinase (PRKAA1). J Clin Pathol 67:758–763. https://doi.org/10.1136/jclinpath-2014-202422
Lee SJ, Kang BW, Chae YS, Kim HJ, Park SY, Park JS, Choi GS, Jeon HS, Lee WK, Kim JG (2014) Genetic variations in STK11, PRKAA1, and TSC1 associated with prognosis for patients with colorectal cancer. Ann Surg Oncol 21(Suppl 4):S634–S639. https://doi.org/10.1245/s10434-014-3729-z
Li Y, He X, Fan L, Zhang X, Xu Y, Xu X (2021) Identification of a novel immune prognostic model in gastric cancer. Clin Transl Oncol 23:846–855. https://doi.org/10.1007/s12094-020-02478-5
Luebeck EG, Curtius K, Jeon J, Hazelton WD (2013) Impact of tumor progression on cancer incidence curves. Cancer Res 73:1086–1096. https://doi.org/10.1158/0008-5472.Can-12-2198
Lutz MP, Zalcberg JR, Ducreux M, Ajani JA, Allum W, Aust D, Bang YJ, Cascinu S, Holscher A, Jankowski J, Jansen EP, Kisslich R, Lordick F, Mariette C, Moehler M, Oyama T, Roth A, Rueschoff J, Ruhstaller T et al (2012) Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer 48:2941–2953. https://doi.org/10.1016/j.ejca.2012.07.029
Picard E, Verschoor CP, Ma GW, Pawelec G (2020) Relationships between immune landscapes, genetic subtypes and responses to immunotherapy in colorectal cancer. Front Immunol 11:369. https://doi.org/10.3389/fimmu.2020.00369
Qin L, Jing X, Qiu Z, Cao W, Jiao Y, Routy JP, Li T (2016) Aging of immune system: immune signature from peripheral blood lymphocyte subsets in 1068 healthy adults. Aging (Albany NY) 8:848–859. https://doi.org/10.18632/aging.100894
Roa J, Barroso A, Ruiz-Pino F, Vazquez MJ, Seoane-Collazo P, Martinez-Sanchez N, Garcia-Galiano D, Ilhan T, Pineda R, Leon S, Manfredi-Lozano M, Heras V, Poutanen M, Castellano JM, Gaytan F, Dieguez C, Pinilla L, Lopez M, Tena-Sempere M (2018) Metabolic regulation of female puberty via hypothalamic AMPK-kisspeptin signaling. Proc Natl Acad Sci U S A 115:E10758–E10767. https://doi.org/10.1073/pnas.1802053115
R. Zhao, C. Peng, C. Song, Q. Zhao, J. Rong, H. Wang, W. Ding, F. Wang and Y. Xie (2020) BICC1 as a novel prognostic biomarker in gastric cancer correlating with immune infiltrates. Int Immunopharmaco l87:106828. https://doi.org/10.1016/j.intimp.2020.106828
Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, Lemmens VE, de Hingh IH (2014) Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer 134:622–628. https://doi.org/10.1002/ijc.28373
Trillo-Tinoco J, Sierra RA, Mohamed E, Cao Y, de Mingo-Pulido A, Gilvary DL, Anadon CM, Costich TL, Wei S, Flores ER, Ruffell B, Conejo-Garcia JR, Rodriguez PC (2019) AMPK alpha-1 intrinsically regulates the function and differentiation of tumor myeloid-derived suppressor cells. Cancer Res 79:5034–5047. https://doi.org/10.1158/0008-5472.CAN-19-0880
Wang L, Brautigan DL (2013) alpha-SNAP inhibits AMPK signaling to reduce mitochondrial biogenesis and dephosphorylates Thr172 in AMPKalpha in vitro. Nat Commun 4:1559. https://doi.org/10.1038/ncomms2565
Wang Y, Li Y, Qiao J, Li N, Qiao S (2019) AMPK alpha1 mediates the protective effect of adiponectin against insulin resistance in INS-1 pancreatic beta cells. Cell Biochem Funct 37:625–632. https://doi.org/10.1002/cbf.3440
Xie J, Fu L, Jin L (2021) Immunotherapy of gastric cancer: past, future perspective and challenges. Pathol Res Pract 218:153322. https://doi.org/10.1016/j.prp.2020.153322
Zhang G (2019) Enhancing VGI application semantics by accounting for spatial bias. Big Earth Data 3:255–268. https://doi.org/10.1080/20964471.2019.1645995
Zhao JJ, Yap DWT, Chan YH, Tan BKJ, Teo CB, Syn NL, Smyth EC, Soon YY, Sundar R (2022) Low programmed death-ligand 1-expressing subgroup outcomes of first-line immune checkpoint inhibitors in gastric or esophageal adenocarcinoma. J Clin Oncol 40:392–402. https://doi.org/10.1200/JCO.21.01862
Zhu H, Foretz M, Xie Z, Zhang M, Zhu Z, Xing J, Leclerc J, Gaudry M, Viollet B, Zou MH (2014) PRKAA1/AMPKalpha1 is required for autophagy-dependent mitochondrial clearance during erythrocyte maturation. Autophagy 10:1522–1534. https://doi.org/10.4161/auto.29197
Funding
This work was supported by the Zhejiang Provincial Natural Science Foundation of China under Grant No. LY21H200001 and No. Q21H160017, Project of Science and Technology Department of Zhejiang Province No. 2022500399, and Zhejiang Province Public Welfare Technology Application Research Project No. 2020KY058 and No. 2021KY082. Pioneer and lead goose of R&D program of Zhejiang No. 2022C03002.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Yongyi Chen, Siyu Chen, Jing Zhu, and Qiong Yu. The first draft of the manuscript was written by Yongyi Chen, Shaoxue Yang, and Songxiao Xu. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethics approval
This study was approved by the local Ethics Committee of the Zhejiang Cancer Hospital (IRB-2021-154).
Consent to participate
Informed consent was obtained from all individual participants included in the study.
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
ESM 1
Supplementary Fig. 1. T (CD3+CD8+) , T (CD3+CD4+) , T (CD3+CD19+) was higher in N0-2 staging. (PNG 193 kb)
ESM 2
Supplementary Fig. 2. Peripheral blood indexes in healthy individuals and GC patients. a Peripheral blood indexes in healthy individuals. b Peripheral blood indexes in GC patients. (PNG 154 kb)
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Chen, Y., Chen, S., Zhu, J. et al. PRKAA1 predicts prognosis and is associated with immune characteristics in gastric cancer. Funct Integr Genomics 23, 252 (2023). https://doi.org/10.1007/s10142-023-01176-z
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s10142-023-01176-z